Life Science Compliance Update

« Previous article | Home| Next article »

February 22, 2017

Valeant and Philidor Controversy Comes to a Head

640x-1

Valeant Pharmaceuticals, Inc. has had quite the year - they have been under scrutiny since October 2015. However, in November 2016, one former Valeant executive and one former Philidor executive, were arrested and charged with criminal complaints. This article outlines those complaints, and the actions the individuals allegedly took to be criminally charged. 

It all started back in October 2015, when a short seller alleged that there was something inappropriate with the relationship between Valeant Pharmaceuticals and its closely linked specialty pharmacy, Philidor. Members of Wall Street – among others – thought that Valeant’s CEO Michael Pearson had a new plan: to create a drug company that focuses on distribution, and let someone else do the research. While controversial, the plan seemed to work for some time, as Valeant’s stock rose to an all-time high of $260.00 per share. What a difference a year makes. Now Valeant stock is trading around $14.00 per share.

Read the full article in the February 2017 issue of Life Science Compliance Update

To Read the Full Story, Subscribe, Download a Sample Issue, or Sign In
PM_LSCU_Box

« Previous article | Home| Next article »

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

The comments to this entry are closed.

Newsletter


Preview | Powered by FeedBlitz

Search


 
Sponsors
September 2017
Sun Mon Tue Wed Thu Fri Sat
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30